[6-K] Sony Group Corporation American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Form 4 highlights for Tarsus Pharmaceuticals (TARS): CFO & Chief Strategy Officer Jeffrey S. Farrow reported the settlement of 27,881 restricted stock units (RSUs) on 16-Jun-2025, converting them into an equal number of common shares (Code M). The following day, 13,608 shares were sold at $40.42 per share (Code S) via a mandatory “sell-to-cover” transaction to satisfy tax-withholding requirements. After these transactions, Farrow directly owns 36,704 common shares and continues to hold 55,763 unvested/undelivered RSUs granted under the 2020 Stock Plan. The reported sale was non-discretionary and does not indicate a change in the insider’s investment outlook. No other derivative activity, option exercises, or discretionary open-market sales were disclosed.

Insights

Senior Securities Analyst

TL;DR: Routine RSU vesting; tax-related sale, minimal market impact.

The filing documents a standard vesting event for 27,881 RSUs granted in 2023. The insider’s subsequent sale of 13,608 shares—roughly 49% of the shares received—was an automatic, issuer-directed action to cover withholding taxes, limiting informational value regarding the executive’s sentiment. Post-transaction ownership remains meaningful at 36,704 shares plus 55,763 RSUs, indicating continued alignment with shareholders. Given Tarsus’ ~27 million shares outstanding, the net share sale represents <0.05% of float and should not materially influence supply-demand dynamics or valuation. Overall, the filing is neutral for investors.

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of July 2025

Commission File Number: 001-06439

SONY GROUP CORPORATION

(Translation of registrant’s name into English)

1-7-1 KONAN, MINATO-KU, TOKYO, 108-0075, JAPAN

(Address of principal executive offices)

The registrant files annual reports under cover of Form 20-F.

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F,

Form 20-F x Form 40-F ¨

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SONY GROUP CORPORATION (Registrant)
	By:	/s/ Lin Tao
		(Signature)
	Lin Tao
	Chief Financial Officer

Date: July 3, 2025

List of Materials

Documents attached hereto:

Notice Regarding the Status of Repurchase of Shares of Common Stock (Repurchase of Shares Under the Provision of Sony’s Articles of Incorporation Pursuant to Article 459, Paragraph 1 of the Companies Act)

July 3, 2025

Sony Group Corporation

Notice Regarding the Status of Repurchase of Shares of Common Stock

(Repurchase of Shares Under the Provision of Sony’s Articles of Incorporation Pursuant to Article 459, Paragraph 1 of the Companies Act)

Sony Group Corporation (“Sony”) announced today the status of the repurchase of shares of its own common stock pursuant to Article 459, Paragraph 1 of the Companies Act of Japan and Article 34 of Sony’s Articles of Incorporation, which was approved at the meeting of its Board of Directors held on May 14, 2025, as follows.

1. Class of shares repurchased:	Common stock of Sony
2. Total number of shares repurchased:	10,772,700 shares
3. Total purchase amount for repurchased shares:	40,295,513,740 yen
4. Period of repurchase:	June 1, 2025 to June 30, 2025
5. Method of repurchase:	Open market purchase through the Tokyo Stock Exchange based on a discretionary trading contract

(For reference)

1. Details of resolution approved at the Board of Directors meeting held on May 14, 2025

(1)	Class of shares to be repurchased	Common stock of Sony
(2)	Total number of shares for repurchase	100 million shares(maximum) (1.66% of total number of shares issued and outstanding (excluding treasury stock))
(3)	Total purchase amount for repurchase of shares	250 billion yen(maximum)
(4)	Period of repurchase	May 15, 2025 to May 14, 2026
(5)	Method of repurchase	Expected open market purchase through the Tokyo Stock Exchange based on a discretionary trading contract

2. Total number and purchase amount of shares repurchased pursuant to the above-mentioned resolution of its Board of Directors (as of June 30, 2025)

(1)	Total number of shares repurchased	18,956,000 shares
(2)	Total purchase amount for repurchased shares	71,263,454,733 yen

End of document

FAQ

How many TARS shares did CFO Jeffrey Farrow acquire and sell?

27,881 shares were acquired through RSU settlement; 13,608 shares were sold to cover taxes.

What price were the TARS shares sold at in the Form 4?

Shares were sold at $40.42 per share on 17-Jun-2025.

Was the insider sale discretionary?

No. The sale was a mandatory “sell-to-cover” for tax withholding, not a discretionary disposition.

How many TARS shares does the CFO still own after the transactions?

Jeffrey Farrow directly owns 36,704 common shares plus 55,763 RSUs that remain unvested/undelivered.

Do these transactions materially affect Tarsus Pharmaceuticals’ share count?

No. The net change is immaterial relative to the company’s total shares outstanding.